%0 Journal Article
%T Pharmacist-led medication review in community-dwelling older patients using the GheOP3 S-tool: General practitioners' acceptance and implementation of pharmacists' recommendations.
%A Foubert K
%A Mehuys E
%A Maesschalck J
%A De Wulf I
%A Wuyts J
%A Foulon V
%A Lelubre M
%A De Vriese C
%A Somers A
%A Petrovic M
%A Boussery K
%J J Eval Clin Pract
%V 26
%N 3
%D Jun 2020
%M 31332905
%F 2.336
%R 10.1111/jep.13241
%X UNASSIGNED: The Ghent Older People's Prescriptions community Pharmacy Screening (GheOP3 S)-tool was recently developed as an explicit screening tool to detect drug-related problems (DRPs) and to help in performing medication reviews. In this study, we aimed (a) to describe the characteristics of the detected DRPs and the subsequent pharmacists' recommendations with their acceptance and implementation rate resulting from a pharmacist-led medication review using the GheOP3 S-tool and (b) to assess the potential impact of the intervention.
METHODS: Prospective observational study in community-dwelling older patients (70 years or older, using five or more medications). Community pharmacists performed medication reviews resulting in the documentation of “GheOP3 S-related DRPs” and “other DRPs” with corresponding pharmacists' recommendations. Acceptance was recorded during face-to-face pharmacist-general practitioner (GP) meetings. Implementation was assessed after a 3-month follow-up by consulting the electronic pharmacy record, the patient, and/or GP. The potential impact on the number of medications, the number of “GheOP3 S-related DRPs”, the anticholinergic and sedative burden quantified by the Drug Burden Index (DBI), and medication costs was assessed by a pre-post comparison of the patients' medication lists.
RESULTS: Twenty-one pharmacists detected 470 DRPs with a median (IQR) of 6 (4-8) per patient in 75 patients (about half “GheOP3 S-related DRPs” and half “other DRPs”). Most prevalent recommendations were stopping (22.9%) and substituting (18.9%) medication. Overall acceptance was 66.9%. At follow-up, 42.9% of all recommendations were implemented. The number of GheOP3 S-criteria (P < .001) and the DBI scores (P = .033) significantly differed from baseline. This was not the case for the number of chronic medications and medication costs.
CONCLUSIONS: This study demonstrates a relatively high acceptance of pharmacists' recommendations, although implementation could be improved. Pharmacist-led medication reviews with multidisciplinary meetings using the GheOP3 S-tool can have a potential impact on the number of DRPs and the anticholinergic and sedative burden of patients.